Aseptuva turns $2.9M seed into preclinical wins, opens Series A
What's the deal? Swiss-UK medtech startup AseptuvaDealroom has a profile for this one. Try Dealroom → raised US$2.2M in a seed round backed by prominent healthcare entrepreneurs and investors. The financing carried the company from early prototyping to preclinical validation in Europe.
What's the endgame? Aseptuva is developing a targeted Far-UVC disinfection technology to prevent hospital-acquired infections, particularly bloodstream infections linked to intravenous catheters. By disinfecting at the catheter-entry site with a non-carcinogenic dose of Far-UVC light, it aims to cut infection risk and reduce reliance on antibiotics.
"With hospitals as our primary customers, our goal is to prevent thousands of avoidable deaths, shorten hospital stays, ease the burden on nursing staff, and save healthcare systems millions in preventable costs," said Henry Twerenbold, chief executive officer and co-founder.
Who backed it? The round drew Simon MichelDealroom has a profile for this one. Try Dealroom →, chief executive officer of Ypsomed; Roger Nitsch, chief executive officer and president of Neurimmune; Armin Diethelm, president of EmitecDealroom has a profile for this one. Try Dealroom →; family office Auxinam; and investment group weInvestDealroom has a profile for this one. Try Dealroom →. Existing investors ValuemakerDealroom has a profile for this one. Try Dealroom → and FortyoneDealroom has a profile for this one. Try Dealroom → added follow-on funding.
"Aseptuva is an exciting example of a Swiss medtech startup addressing a clinical need with strong market potential," said Michel. "The team convinced me of its ability to navigate the challenges ahead."
What's the progress? Since the raise, Aseptuva has run more than 50 interviews with clinical staff across eight hospitals in Europe and the US. It developed a prototype with Philips Innovation ServicesDealroom has a profile for this one. Try Dealroom →, Fraunhofer FEPDealroom has a profile for this one. Try Dealroom →, and Laser Zentrum HannoverDealroom has a profile for this one. Try Dealroom →, then passed preclinical efficacy testing in the UK. A recent study using a 3D human skin model found no adverse biological effects under the tested conditions.
Why now? Building on that progress, Aseptuva is opening a US$4.58M Series A to fund clinical development, UK expansion, and US market entry. Existing shareholders have already committed more than US$366.7K in additional funding.
Unlike many deeptech ventures, Aseptuva was founded independently in 2021 rather than as an academic spinout. It has secured competitive funding from InnosuisseDealroom has a profile for this one. Try Dealroom →, Horizon EuropeDealroom has a profile for this one. Try Dealroom →, NIHRDealroom has a profile for this one. Try Dealroom →, and Innovate UKDealroom has a profile for this one. Try Dealroom →.
The signal: The seed round lands in the top tier for size among comparable deals, a marker of investor conviction in a company tackling antimicrobial resistance — a growing priority for healthcare systems worldwide.
Read more: startupticker.ch
Image credit: Generated with Gemini
